ImmuCell Corporation
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $88.0M
- Price
- $9.69
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.81%
- Volume
- 5.2K
About
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
Quick stats
Shares outstanding9.1M
Computed float6.0M
Float / shares66.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000811641
Websitehttps://immucell.com
AI Summary
AI-generated1/12
majorbullishearnings
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
ImmuCell reported Q2 revenue of $7.2 million, up 11.5% year-over-year, with net income rising to $1.8 million or $0.20 per diluted share.
Cash and cash equivalents increased significantly to $8.9 million, aided by a one-time $2 million settlement payment from a former contract manufacturer, though gross margins contracted to 34% due to lower volumes and manufacturing scrap.
The company authorized a two-phase capacity expansion program totaling approximately $8 million to triple production capacity for its First Defense product line over the next 18 months.
Red flags
- Gross margin declined to 33.9% from 43.7% year-over-year due to manufacturing headwinds and quality issues
- Net income included a non-recurring $2 million legal settlement payment